Search for: "BM" Results 21 - 40 of 430
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
5 Jul 2012, 11:53 am by Tiffany Schmidt
The Bureau of Mediation Services (BMS) recently issued a decision which could have broad implications. [read post]
13 Apr 2015, 3:00 am by Steve Brachmann
Food and Drug Administration approved the use of BMS’s immunotherapy drug Opvido for the treatment of lung cancer. [read post]
17 Aug 2022, 12:19 pm by Daily Record Staff
BMS will implement the expansion over the next three years, adding new staff, increased outreach and new referral programs with ... [read post]
21 Apr 2021, 6:05 am by Daily Record Staff
The BMS DEAL program will launch May 1 and is funded for ... [read post]
8 Feb 2024, 12:59 pm by Daily Record Staff
Baltimore Medical System (BMS), the largest Federally Qualified Health Center (FQHC) system in Maryland, Thursday was recently awarded two grants that will support new and ongoing efforts to address disparities in cancer early detection among patients in Baltimore. [read post]
12 Sep 2012, 8:51 am by Tiffany Schmidt
He indicated the City was notified by the BMS the part-time firefighters withdrew their petition to unionize. [read post]
30 Apr 2021, 10:23 am by jeffreynewmanadmin
Of that amount, BMS will pay approximately $41 million, plus interest, to the United States, and the remainder to states participating in the settlement. [read post]
21 Nov 2008, 3:43 pm
" The manuscript is due to go to publishers in January, after Behrman's nondisclosure agreement with BMS expires.No word yet about the joy over at BMS related to this announcement.Source NY Daily News.Additional web pages: InSync Communication, Drug Expert Witness. [read post]
16 Nov 2011, 5:12 am by abogados-i
Nº 1029/AGIP/2011) Buenos Aires, 16 de noviembre de 2011 VISTO: La Ley Nº 2603 (BOCBA Nº 2.846), el Decreto 1126/1993 (BM Nº 19.603), el Decreto 674/1995 (BM Nº 20.084) y la Resolución Nº 430-SHyF/2001 (BOCBA Nº 1.170) y, CONSIDERANDO: Que por los Decretos Nros. 1126/93 y 674/95 se instrumentó oportunamente un régimen de percepción [read post]
(“Sawai”) to suspend the manufacture and sale of Sawai’s pharmaceutical product (“Sawai’s Product”) developed and sold as a generic drug of Bristol-Myers Squibb (“BMS”)’s cancer drug “Sprycel®” (Case No. 2023 (Yo) 30214; AIK represented BMS in this case). [read post]
8 Sep 2016, 3:07 pm by Michael Walsh
  The majority also concluded that BMS’s unrelated California research provided an additional connection regarding plaintiffs’ claims that BMS negligently researched the subject product, as well as increasing BMS’s overall contact with California. [read post]